301201 Chengda Pharmaceuticals
- 19.00
- -0.73-3.70%
Chengda Pharmaceuticals News
Chengd Pharmaceutical (301201.SZ): Some fundraising projects have been completed.
On January 3, Gelonghui reported that Chengda Pharmaceutical Co., Ltd. (301201.SZ) announced that recently, the fundraising investment projects "Pharmaceutical Intermediate Project" and "Active Pharmaceutical Ingredient Project" have been completed and reached the designated usable status, meeting the project completion conditions. Therefore, the company has decided to conclude the "Pharmaceutical Intermediate Project" and "Active Pharmaceutical Ingredient Project."
Express News | Chengda Pharmaceutical: Completion of pharmaceutical intermediates project and Active Pharmaceutical Ingredient project.
Express News | Chengda Pharmaceutical: Re-certified as a high-tech enterprise.
Chengda Pharmaceutical (301201.SZ): Active Pharmaceutical Ingredients such as Edaravone Sodium and Rivaroxaban are currently under registration application.
On December 17, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) stated in a recent investor relations activity that the Active Pharmaceutical Ingredient L-carnitine has been approved by the regulatory authorities of several countries and obtained the CEP certification in Europe, covering quality system certification for major global markets. The Active Pharmaceutical Ingredient Brinfido has been approved by South Korea's MFDS, while the Active Pharmaceutical Ingredients Aflibercept and Rivaroxaban are in the process of registration. The Active Pharmaceutical Ingredient Daglizhuo passed CDE approval in November 2024, further enriching the company's product line.
Express News | Overview of Share Buyback in A-shares: 16 companies disclose buyback progress.
Chengda Pharmaceutical (301201.SZ): The L-carnitine series products are exported to over 30 global countries, with stable quality.
On December 9, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) recently stated in an investor relations activity that the company's L-carnitine series products are exported to over 30 countries globally, with stable quality and a good international reputation, making it one of the main suppliers of L-carnitine worldwide. Currently, the sales prices of the company's L-carnitine products are relatively stable, having slightly improved from the lowest market prices, but there remains a certain level of uncertainty regarding the future price trend of related products.
Chengda Pharmaceuticals (301201.SZ): A total of 2.10% of shares have been repurchased.
On December 3rd, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) announced that as of November 30, 2024, the company has repurchased a total of 3,244,700 shares through a dedicated securities repurchase account via centralized bidding trade, accounting for 2.10% of the company's current total share capital, with a highest fill price of 22.21 yuan/share, a lowest fill price of 14.63 yuan/share, and a total transaction amount of 57,061,614.15 yuan (excluding transaction fees).
November 22nd A-share investment lightning rod︱Changguang Huaxin: Shareholders Guotou Chuangye Ningbo Fund, Yili Suxin, and Nanjing Daofeng plan to collectively reduce their shareholding by no more than 2.01%.
*Shenzhen Coship Electronics: Termination of the application for reorganization and pre-reorganization to the court.
Express News | Chengda Pharmaceutical: Shareholder Qianhai Shengtai plans to reduce their shareholding by no more than 4.22% of the company's shares.
Express News | Chengda Pharmaceuticals: The active pharmaceutical ingredient Daglielin has passed the CDE approval.
Chengda Pharmaceutical: Report for the third quarter of 2024
Chengda Pharmaceutical (301201.SZ) released its performance for the first three quarters, with a net income of 40.3928 million yuan, a decrease of 33.98%.
Chengda Pharmaceutical (301201.SZ) released the third quarter report of 2024, the company's revenue for the first three quarters is 2...
Chengda Pharmaceutical (301201.SZ): has cumulatively repurchased 2.10% of its shares.
Gelonghui October 10th | Chengda Pharmaceutical (301201.SZ) announced that as of September 30, 2024, the company has repurchased a total of 3,244,700 shares of the company through a repurchase special securities account in a centralized auction trading manner, accounting for 2.10% of the company's total share capital. The highest fill price was 22.21 yuan/share, the lowest fill price was 14.63 yuan/share, and the total trade amount was 57.0616 million yuan (excluding trading fees).
Chengda Pharmaceuticals (301201.SZ): At present, the sales price of the company's L-carnitine products is relatively stable, slightly improved compared to the lowest market conditions.
On September 29, Gelonghui reported that Chengda Pharmaceutical (301201.SZ) stated during a specific research session that the current sales price of the company's L-carnitine products is relatively stable, showing a slight improvement compared to the lowest market price. There is still some uncertainty about the future price trends of related products.
Chengda Pharmaceutical: 2024 Semi-Annual Report
Chengda Pharmaceutical: 2024 Semi-Annual Report Summary
Chengda Pharmaceutical (301201.SZ) released its performance for the first half of the year, with a net income of 25.1748 million yuan, a decrease of 14.23%.
Chengda Pharmaceutical (301201.SZ) released its 2024 interim report, with revenue of 0.164 billion...
Express News | Chengda Pharmaceutical: Net income in the first half of 2024 decreased by 14.23% compared to the same period last year.
Chengda Pharmaceutical (301201.SZ): has repurchased 2.03% of its shares to date.
Chengda Pharmaceutical (301201.SZ) announced that as of July 31, 2024, the company has accumulated the repurchase of 3,137,500 shares through a repurchase special securities account using centralized bidding trading method, accounting for 2.03% of the company's current total share capital. The highest fill price was 22.21 yuan/share, and the lowest fill price was 14.63 yuan/share. The total trade amount was 55,266,670.15 yuan (excluding transaction costs).
Chengda Pharmaceutical (301201.SZ) plans to distribute 2 yuan for every 10 shares, with ex-rights and ex-dividend dates on July 10.
Chengda Pharmaceutical (301201.SZ) announced that it plans to distribute equity to all shareholders in 2023: 1 bonus share for every 10 shares held and a cash dividend of 0.5 yuan (tax included) per share.
No Data
